Komori
Earnings4592SanBio Company LimitedPharmaceuticals

Notice Regarding the Recognition of Non-operating Income and Adjustments to Income Taxes

In the first quarter of the fiscal year ending January 2027, the Company recorded a foreign exchange gain of ¥177 million as non-operating income due to fluctuations in foreign exchange rates. It also recognized deferred tax liabilities relating to foreign-currency-denominated loans to consolidated subsidiaries and other items, and recorded deferred income tax expense of ¥55 million.

Worth reading
25Immaterial
Scored from 3 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
177
¥ million
Wording
Definitive
How definitive the wording is.

Results for this period

First quarter1 February 2026–30 April 2026
Factors Behind Changes in Business Performance

Foreign exchange gains arose due to fluctuations in foreign exchange rates. The Company recognized deferred tax liabilities relating to foreign-currency-denominated loans to consolidated subsidiaries and related receivables.

Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Period Covered1 February 2026–30 April 2026
Factors Behind Changes in Business PerformanceForeign exchange gains arose due to fluctuations in foreign exchange rates. The Company recognized deferred tax liabilities relating to foreign-currency-denominated loans to consolidated subsidiaries and related receivables.
Items this document does not state (35)
Accounting standardsConsolidated / non-consolidatedNet SalesOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Foreign exchange gains arose on foreign-currency-denominated loans to consolidated subsidiaries and related receivables due to fluctuations in foreign exchange rates. The Company also recognized deferred tax liabilities relating to these items.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recognition of Non-operating Income and Adjustments to Income Taxes | SanBio Company Limited (4592) timely disclosure | Komori